Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA lays out tips, sets deadlines for UDI direct-marking of reprocessed devices

This article was originally published in Clinica

Executive Summary

Reprocessed and re-used life-sustaining and life-supporting devices, regardless of their classification, will need to have unique device identifiers (UDI) directly marked on them by September 2016 according to a new FDA draft guidance which lays out a timeline that would require all other necessary devices follow direct marking requirements by the end of 2020.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel